Vividion Therapeutics to Expand with New Global Research and Development Center
2024年7月23日 - 3:30PM
ビジネスワイヤ(英語)
- New facility in San Diego will support continued development of
Vividion’s global discovery and clinical portfolio and pave the way
for future programs aimed at bringing first-in-class therapeutics
to patients in need
- Chemoproteomics screening capacity will increase by 50 percent
to enable Vividion to pursue an expansive range of previously
undrugged disease targets
Vividion Therapeutics, Inc. (Vividion), a clinical stage
biopharmaceutical company utilizing novel discovery technologies to
unlock high-value, traditionally undruggable targets with precision
therapeutics for devastating cancers and immune disorders, today
announced it will expand its global innovation capabilities with a
new research and development (R&D) center and corporate
headquarters in San Diego, California. Vividion is a wholly owned
and independently operating subsidiary of Bayer AG.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240722153054/en/
The new facility will support the continued development of
Vividion’s R&D capabilities, including a significant increase
in the company’s chemoproteomics screening capacity. More than half
of the expansion will be dedicated to state-of-the-art research
labs where Vividion will continue advancing its expansive portfolio
of clinical and preclinical programs as well as future programs
that emerge from the company’s discovery efforts. The new facility
will accommodate strategic growth capabilities and enable the
company to continue to attract and retain top life sciences experts
in San Diego, a rapidly growing hub for biotech innovation.
“Vividion has entered an exciting new stage in the company’s
development, with multiple programs in clinical trials, a rich
discovery portfolio and expansive platform screening efforts
focused on bringing more previously undrugged disease-causing
targets within the reach of small molecule therapeutics. Our new
R&D center and headquarters will provide the infrastructure to
execute our strategic vision and continue to lead the way in
applying chemoproteomics and covalent chemistry to create
first-in-class medicines for patients in need,” said Aleksandra
Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “Vividion’s
culture of innovation has always been driven by outstanding people
working collaboratively in a dynamic and supportive environment.
We’re looking forward to continuing and building on that tradition
in our new state-of-the-art home.”
“Vividion is a key component of Bayer’s innovation strategy and
its focus on bringing first-in-class medicines to market to address
longstanding unmet medical needs,” said Stefan Oelrich, Member of
the Board of Management of Bayer AG and President Pharmaceuticals
at Bayer. “This new facility will support our strategic growth
opportunities to enable the company to capitalize on the rich array
of drug discovery and clinical development opportunities afforded
by its pioneering chemoproteomics platform.”
Bayer has a long-standing track record of delivering scientific
innovation for patients. Rebuilding the portfolio, enhancing
R&D capabilities, and an ongoing reallocation of resources –
including commitment to building on its strong presence in the
United States – are key parts of the company’s strategy to achieve
sustainable long-term growth. San Diego’s world-renowned biotech
cluster is home to hundreds of life science companies and leading
research institutes that have made significant contributions to
advancements in healthcare. Such an ecosystem holds great promise
for Bayer to strengthen its leadership and innovation pipeline. In
addition to San Diego, Bayer has successfully developed a local
presence in each of the United States’ most innovative life science
hubs, including Boston, San Francisco and Research Triangle Park -
North Carolina.
About Vividion Vividion Therapeutics, Inc., a wholly
owned and independently operated subsidiary of Bayer AG, is a
clinical stage biopharmaceutical company utilizing novel discovery
technologies to unlock high value, traditionally undruggable
targets with precision therapeutics for devastating cancers and
immune disorders. The company’s platform has enabled it to identify
hundreds of previously unknown functional pockets on well-validated
protein targets implicated in a wide range of diseases, while
simultaneously identifying compounds from its proprietary covalent
chemistry library that interact in a highly selective manner with
those pockets. The company is leveraging its proprietary
chemoproteomic platform to advance a diversified pipeline of highly
selective small molecule therapeutics targeting high value,
traditionally undruggable targets in oncology and immunology. For
more information, please visit www.vividion.com.
About Bayer Bayer is a global enterprise with core
competencies in the life science fields of health care and
nutrition. In line with its mission, “Health for all, Hunger for
none,” the company’s products and services are designed to help
people and the planet thrive by supporting efforts to master the
major challenges presented by a growing and aging global
population. Bayer is committed to driving sustainable development
and generating a positive impact with its businesses. At the same
time, the Group aims to increase its earning power and create value
through innovation and growth. The Bayer brand stands for trust,
reliability and quality throughout the world. In fiscal 2023, the
Group employed around 100,000 people and had sales of 47.6 billion
euros. R&D expenses before special items amounted to 5.8
billion euros. For more information, go to www.bayer.com.
Find more information about Vividion at www.vividion.com Find
more information at https://pharma.bayer.com/ Follow us on
Facebook: http://www.facebook.com/bayer
lh (2024-0037E)
Forward-Looking Statements This release may contain
forward-looking statements based on current assumptions and
forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given
here. These factors include those discussed in Bayer’s public
reports which are available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722153054/en/
Vividion Media: Laurie Sherman,
phone +1 858.630.8246 Email: media@vividion.com
Bayer Media: Lisa Hennig, phone
+49 172 8693420 Email: lisa.hennig@bayer.com
Bayer U.S. Media: Elaine Colon,
phone +1 (732) 2361587 Email: elaine.colon@bayer.com